
My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.
Diffuse large B-cell lymphoma (DLBCL) can present de novo or transform from a less aggressive lymphoma. The pathogenesis of DLBCL is a multistep process that involves genetic alterations, immune status of the patient and tumour microenvironment. The Human Leukocyte Antigen (HLA) system regulates the immune response and loss of HLA expression in the tumour cells leads to an altered host immunity and impairs effective anti-tumour responses. Our aim is to investigate the proteome of tumor cells to identify proteins that play a role in the cross talk between tumor cells and the microenvironment in DLBCL. The ultimate goal is to explain why patients react differently to therapy and to provide a tailored treatment plan in order to avoid over- and undertreatment.
In this thesis we determined the cell populations of microenvironment of cHL and NLPHL in general and with a specific focus on the cells in close vicinity of the neoplastic cells. Current thesis indicates that the combination of microenvironment of cHL in Epstein Barr virus infected cHL cases (EBV+ cHL) is different compared to EBV- cHL cases, which might be due specific reaction of immune system against this virus. On the other hand, the combination of microenvironment of NLPHL indicates a significant population of TFH cells. Subsequent study also suggests that the TFH cells form rosette around neoplastic cells of the NLPHL. In addition, comparison of the cell populations of cHL and NLPHL indicate differences in combination of microenvironments of two subtypes. This fact suggests that each sub-type, applies different mechanisms for survive.
In the first part we investigated changes in the expression levels of membrane proteins of non Hodgkin lymphoma (NHL) cell lines compared with a lymphoblastoid cell line. We found differential expression of peptidylprolyl isomerase A which can be considered as a potential target for treatment of lymphoma patients. Next, we profiled the secretome of NHL cell lines and identified potential novel disease biomarkers such as macrophage inhibition factor and CD70.
In the second part, we analyzed the composition of tonsil and reactive lymph node (RLN) to select the best normal counterpart for the subsequent analysis of the B cell lymphoma samples. Then, we compared the composition of the microenvironment of different NHL as well as Hodgkin lymphoma (HL) with RLN. We found more cytotoxic T cells in more aggressive lymphomas, these cells are probably in an hypo-immune response status since they showed high expression of an exhaustion marker. Converting the exhaustive phenotype of the T cells might present a novel treatment strategy to induce an effective immune response in B cell lymphomas. In HL we found that the percentage of T regulatory cells is high in the tumor areas and that these cells most likely suppress the immune response.
In this thesis we determined the cell populations of microenvironment of cHL and NLPHL in general and with a specific focus on the cells in close vicinity of the neoplastic cells. Current thesis indicates that the combination of microenvironment of cHL in Epstein Barr virus infected cHL cases (EBV+ cHL) is different compared to EBV- cHL cases, which might be due specific reaction of immune system against this virus. On the other hand, the combination of microenvironment of NLPHL indicates a significant population of TFH cells. Subsequent study also suggests that the TFH cells form rosette around neoplastic cells of the NLPHL. In addition, comparison of the cell populations of cHL and NLPHL indicate differences in combination of microenvironments of two subtypes. This fact suggests that each sub-type, applies different mechanisms for survive.
In the first part we investigated changes in the expression levels of membrane proteins of non Hodgkin lymphoma (NHL) cell lines compared with a lymphoblastoid cell line. We found differential expression of peptidylprolyl isomerase A which can be considered as a potential target for treatment of lymphoma patients. Next, we profiled the secretome of NHL cell lines and identified potential novel disease biomarkers such as macrophage inhibition factor and CD70.
In the second part, we analyzed the composition of tonsil and reactive lymph node (RLN) to select the best normal counterpart for the subsequent analysis of the B cell lymphoma samples. Then, we compared the composition of the microenvironment of different NHL as well as Hodgkin lymphoma (HL) with RLN. We found more cytotoxic T cells in more aggressive lymphomas, these cells are probably in an hypo-immune response status since they showed high expression of an exhaustion marker. Converting the exhaustive phenotype of the T cells might present a novel treatment strategy to induce an effective immune response in B cell lymphomas. In HL we found that the percentage of T regulatory cells is high in the tumor areas and that these cells most likely suppress the immune response.